C3.ai, Inc.
-$495.10M- Market cap
- $36.61M
- Debt
- +$43.74M
- Cash
- −$575.45M
Capital structure 46% equity / 54% debt · EV / EBITDA 1.09x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: AI stock price at premium vs JAZZ $10.46 current versus $6.69 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at JAZZ's multiple
Implied fair value · at AI's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AI FY 2026 (ended Apr 30, 2026) · JAZZ FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 46% equity / 54% debt · EV / EBITDA 1.09x
Capital structure 71% equity / 29% debt · EV / Revenue 4.92x · EV / EBITDA 66.46x
JAZZ carries the larger enterprise value at $21.02B against -$495.10M; AI trades on the lower EV / EBITDA multiple (1.09x vs 66.46x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
C3.ai, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Jazz Pharmaceuticals plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.07x
1.48x
Net debt / EBITDA
Leverage against operating earnings
1.17x
15.80x
Cash and equivalents
Liquid reserves on the balance sheet
$575.45M
$1.39B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ORACLE CORP
AI vs ORCL
ServiceNow, Inc.
AI vs NOW
Palantir Technologies Inc.
AI vs PLTR
Snowflake Inc.
AI vs SNOW
UiPath, Inc.
AI vs PATH
PEGASYSTEMS INC
AI vs PEGA
AMGEN INC
AI vs AMGN
GILEAD SCIENCES, INC.
AI vs GILD
VERTEX PHARMACEUTICALS INC / MA
AI vs VRTX
SUPERNUS PHARMACEUTICALS, INC.
AI vs SUPN
Vanda Pharmaceuticals Inc.
AI vs VNDA
PERRIGO Co plc
AI vs PRGO
$43.74M
$6.39B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.